Tofersen: First Approval
- PMID: 37316681
- DOI: 10.1007/s40265-023-01904-6
Tofersen: First Approval
Abstract
Tofersen (Qalsody™) is an antisense oligonucleotide being developed by Biogen for the treatment of amyotrophic lateral sclerosis (ALS). On 25 April 2023, tofersen was approved in the USA for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This article summarizes the milestones in the development of tofersen leading to this first approval for ALS.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26(9 Suppl):S191–7. - PubMed
-
- de Courssou J-BB, Durr A, Adams D, et al. Antisense therapies in neurological diseases. Brain. 2022;145(3):816–31. - DOI
-
- Biogen MA Inc. QALSODY (tofersen) injection, for intrathecal use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf . Accessed 30 May 2023.
-
- Biogen IP. Biogen exercises option with Ionis to develop and commercialize investigational treatment BIIB067 for a subtype of familial amyotrophic lateral sclerosis (ALS) based on positive phase 1 data [media release]. 6 Dec 2018. http://www.biogen.com .
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous